HK Stock Market Move | Suzhou Dongshan Precision Manufacturing (02384) rises over 4%; controlling shareholder proposes annual return of no less than RMB1 billion; third-quarter performance this year grows rapidly.
Suzhou Dongshan Precision Manufacturing (02384) rose over 4%. As of press time, it was up 4.60% at HK$78.45, with a turnover of HK$5.5169 million.
Suzhou Dongshan Precision Manufacturing (02384) rose over 4%, up 4.60% as of press time at HK$78.45, with turnover of HK$5.5169 million.
On the news front, on the evening of November 3, Suzhou Dongshan Precision Manufacturing announced that its controlling shareholder proposed that, subject to meeting profit distribution conditions and without affecting the company's going concern and long-term development, the total shareholder return for the 2026 fiscal year should be no less than RMB1 billion, including cash dividends and share repurchase amounts. Meanwhile, if the company's operating performance continues to grow in the 2027 and 2028 fiscal years, it is recommended that, based on the total shareholder return for the 2026 fiscal year, the return scale be appropriately increased year by year in light of actual operating conditions.
In the third quarter of this year, Suzhou Dongshan Precision Manufacturing achieved operating revenue of RMB17.582 billion, up 73.81% year on year; net profit attributable to shareholders of the parent company was RMB2.332 billion, up 401.18% year on year; net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was RMB2.099 billion, up 406.69% year on year. The high performance growth was mainly driven by the consolidation of Source Photonics and GMD, the explosive growth of the optical module business, and the steady growth of traditional businesses.
Related Articles

Goldman Sachs: Raises Hong Kong's 2026 GDP growth forecast to 5%, 2027 forecast up to 3.1%
HK Stock Market Move | CSTONE PHARMA-B (02616) rises nearly 4% on clinical development collaboration with Kimia to jointly advance a drug with first-in-class potential.

HK Stock Market Move | ACTIVATION GP (09919) rises over 5%; interim profit attributable to shareholders RMB22.879 million; cumulative repurchase of 1.38 million shares during the year.
Goldman Sachs: Raises Hong Kong's 2026 GDP growth forecast to 5%, 2027 forecast up to 3.1%

HK Stock Market Move | CSTONE PHARMA-B (02616) rises nearly 4% on clinical development collaboration with Kimia to jointly advance a drug with first-in-class potential.
HK Stock Market Move | ACTIVATION GP (09919) rises over 5%; interim profit attributable to shareholders RMB22.879 million; cumulative repurchase of 1.38 million shares during the year.






